NRAS and melanoma: BRAF inhibitors, including vemurafenib and dabrafenib, have demonstrated efficacy in patients with BRAF-mutated melanoma [9–11]; however, no targeted therapy has been approved for patients with melanoma harboring NRAS mutations to date.